SCHEMBL8086791

SCHEMBL8086791

C=C(Nc1cccc(OC)c1)c1ccc(NCC)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
KMT2A Q03164 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
TP53 P04637 2/20 0.51
ALDH1A1 P00352 2/20 0.51
PKM P14618 1/20 0.51
MAPT P10636 3/20 0.50
MEN1 O00255 3/20 0.50
TSHR P16473 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49
HPGD P15428 1/20 0.48
NLRP3 Q96P20 1/20 0.48
LMNA P02545 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
MTNR1B P49286 2/20 0.47
MTNR1A P48039 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
IDO1 P14902 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254156 0.84 NPC1 (0.74) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL8071365 0.83 NPC1 (0.56) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL8086764 0.80 RAB9A (0.45) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL8079371 0.80 NPC1 (0.65) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL8086822 0.80 ROCK2 (0.55) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL38660132 0.79 MTNR1B (0.57) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL42399 0.79 MTNR1B (0.57) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL8091906 0.78 NPC1 (0.56) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL28471149 0.77 MTNR1B (0.55) NPC1RAB9AKMT2ASMN1; SMN2TP53
SCHEMBL13391762 0.76 KMT2A (0.69) NPC1RAB9AKMT2ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009016088-A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 WO disclosed